logo
Plus   Neg
Share
Email

Dermira Does It Again!

Cimzia-120816.jpg

A little over two months after reporting positive results from its first late-stage psoriasis trial, Dermira Inc. (DERM) is back with some more good news for its investors.

The company's second of three phase III psoriasis trials, dubbed CIMPASI-1, evaluating the efficacy and safety of Cimzia in adult patients with moderate-to-severe chronic plaque psoriasis has demonstrated statistically significant improvements for both co-primary efficacy endpoints compared to placebo.

In the CIMPASI-1 study, a total of 234 patients with moderate-to-severe chronic plaque psoriasis were randomized to three dosing arms - 400 mg every two weeks, 400 mg at weeks 0, 2, and 4 followed by 200 mg every two weeks, or placebo every two weeks.

The company reported positive results from the first phase III study of Cimzia in adult patients with moderate-to-severe chronic plaque psoriasis in October of this year.

The data from the third and final phase III trial of Cimzia, known by the name CIMPACT, is pending, and that is expected in the first quarter of 2017.

Cimzia is currently approved and marketed by Belgium-based biopharmaceutical firm UCB Pharma S.A. for the treatment of numerous inflammatory diseases like Crohn's disease, rheumatoid arthritis and psoriatic arthritis in adults in multiple countries, including the United States. Cimzia brought home net sales of 933 million euros for UCB in the first nine months of 2016 compared to 775 million euros a year ago.

In July 2014, UCB granted Dermira an exclusive license to develop Cimzia in psoriasis in the U.S., Canada and the European Union.

DERM closed Wednesday's trading at $29.86, down 4.93%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT